Abstract
Currently available therapies for brain ischemia, with a few exceptions, provide only symptomaticrelief in patients. Recent investigations in experimental models provided an understanding of the cellular andmolecular mechanisms that lead to neurodegeneration in ischemic injury, and also indicate targets forprevention and amelioration of the devastating consequences of stroke. An enormous increase in intracellularfree Ca2+ levels following stroke activates Ca2+-dependent enzymes, contributing to neuronal death anddysfunction. Additionally, ischemic injury generates highly reactive free radicals and triggers release ofcytotoxic cytokines for activation of cysteine proteases. A number of studies already indicated a prominentrole for the cysteine proteases of the calpain and caspase families in the pathogenesis of brain ischemia.Proteolytic activities of these proteases degrade various cytoskeletal proteins and membrane proteins,destabilizing the structural integrity and forcing the neurons to delayed de ath in ischemic penumbra. Somecurrent studies have unequivocally confirmed the neuronal apoptosis in ischemia and showed thatadministration of calpain and caspase inhibitors alone or in combination can provide functionalneuroprotection in various animal models of cerebral ischemia. This article will discuss the molecularstructures and activities of calpain and caspase inhibitors and their therapeutic efficacy in experimental brainischemia. However, further investigations are necessary for improvements in the structural design of calpainand caspase inhibitors for their persistent therapeutic efficacy in animal models of stroke and for clinical trialsin the future.
Keywords: Brain ischemia, Ca2+ influx, Calpain, Caspases, Inhibitors, Proteolytic activities, Neurodegeneration, Neuroprotection
Current Medicinal Chemistry
Title: Currently Evaluated Calpain and Caspase Inhibitors for Neuroprotection in Experimental Brain Ischemia
Volume: 13 Issue: 28
Author(s): Swapan K. Ray
Affiliation:
Keywords: Brain ischemia, Ca2+ influx, Calpain, Caspases, Inhibitors, Proteolytic activities, Neurodegeneration, Neuroprotection
Abstract: Currently available therapies for brain ischemia, with a few exceptions, provide only symptomaticrelief in patients. Recent investigations in experimental models provided an understanding of the cellular andmolecular mechanisms that lead to neurodegeneration in ischemic injury, and also indicate targets forprevention and amelioration of the devastating consequences of stroke. An enormous increase in intracellularfree Ca2+ levels following stroke activates Ca2+-dependent enzymes, contributing to neuronal death anddysfunction. Additionally, ischemic injury generates highly reactive free radicals and triggers release ofcytotoxic cytokines for activation of cysteine proteases. A number of studies already indicated a prominentrole for the cysteine proteases of the calpain and caspase families in the pathogenesis of brain ischemia.Proteolytic activities of these proteases degrade various cytoskeletal proteins and membrane proteins,destabilizing the structural integrity and forcing the neurons to delayed de ath in ischemic penumbra. Somecurrent studies have unequivocally confirmed the neuronal apoptosis in ischemia and showed thatadministration of calpain and caspase inhibitors alone or in combination can provide functionalneuroprotection in various animal models of cerebral ischemia. This article will discuss the molecularstructures and activities of calpain and caspase inhibitors and their therapeutic efficacy in experimental brainischemia. However, further investigations are necessary for improvements in the structural design of calpainand caspase inhibitors for their persistent therapeutic efficacy in animal models of stroke and for clinical trialsin the future.
Export Options
About this article
Cite this article as:
Ray K. Swapan, Currently Evaluated Calpain and Caspase Inhibitors for Neuroprotection in Experimental Brain Ischemia, Current Medicinal Chemistry 2006; 13 (28) . https://dx.doi.org/10.2174/092986706779010342
DOI https://dx.doi.org/10.2174/092986706779010342 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Targeting of Peripherally Expressed Pain-Related Molecules in Injury- Induced Chronic Neuropathic Pain
CNS & Neurological Disorders - Drug Targets The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Use of Methotrexate in Respiratory Diseases
Current Respiratory Medicine Reviews Vascular Effects of Insulin and Their Relation to Endothelial Dysfunction, Insulin Resistance and Hypertension
Current Hypertension Reviews Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Mitochondrial-Targeted Antioxidants and Oxidative Stress: A Proteomic Prospective Study
Current Pharmaceutical Design Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets The Role of Neurogenic Bioamines in Nerve Fibers of Uterus during the Postpartum Involution in Experimental Animal Models
Current Pharmaceutical Design Meet Our Co-Editor
Current Enzyme Inhibition NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Hemichannels in Cerebral Ischemia
Current Molecular Medicine Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets HIV Pharmacogenetics in Clinical Practice: Recent Achievements and Future Challenges
Current HIV Research Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Biosynthetic Pathways of Bioactive N-Acylethanolamines in Brain
CNS & Neurological Disorders - Drug Targets Evaluation of HIV-1 Regulatory and Structural Proteins as Antigen Candidate in Mice and Humans
Current HIV Research Achievements and Bottlenecks of PEGylation in Nano-delivery Systems
Current Medicinal Chemistry